{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:07:24Z","timestamp":1759334844340,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.jaad.2009.11.034","type":"journal-article","created":{"date-parts":[[2011,6,24]],"date-time":"2011-06-24T15:31:20Z","timestamp":1308929480000},"page":"224-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis"],"prefix":"10.1016","volume":"65","author":[{"given":"Anja Gunda","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Horny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Sotlar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Overbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Peter","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Undine","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2009.11.034_bib1","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaad.2009.11.034_bib2","series-title":"World Health Organization classification of tumours. Pathology and genetics of tumours of the haematopoietic and lymphoid tissues","first-page":"291","article-title":"Mastocytosis (Mast Cell Disease)","author":"Valent","year":"2001"},{"key":"10.1016\/j.jaad.2009.11.034_bib3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0145-2126(01)00028-5","article-title":"Classes of c-kit activating mutations: proposed mechanisms of action and implications for disease classification and therapy","volume":"25","author":"Longley","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaad.2009.11.034_bib4","first-page":"672","article-title":"Mast cells in atherosclerosis as a source of RANKL","volume":"44","author":"Ali","year":"2006","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jaad.2009.11.034_bib5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000063858","article-title":"Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients","volume":"128","author":"Theoharides","year":"2002","journal-title":"Int Arch Allergy Immunol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962209015047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962209015047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:19:26Z","timestamp":1759270766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962209015047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0190962209015047"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2009.11.034","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2009.11.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}